IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Basic Trial Information
IoN is a phase II/ III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients.
Further Study Information
Phase II: to determine if recruitment into a phase III trial is feasible, with a target of 10 patients per month during a minimum of 6 months (evaluated within months 7-18 of the trial).
Phase III: to determine whether the 5-year disease-free survival rate among patients who do not have routine Radioactive iodine (RAI) ablation is non-inferior to those who do.
Trial Contact Information
Trial Lead Organizations/Sponsors
University College Hospital - London
Ujjal K. Mallick, Principal Investigator
Jonathan A. Ledermann, Study Director
Ph: 020 7679 9392
University Hospitals Birmingham NHS Foundation Trust
University Hospitals Bristol NHS Foundation Trust
Mid Essex Hospitals Services NHS Trust
Gloucestershire Hospitals NHS Trust
Dorset Cancer Centre
Royal Devon and Exeter Hospital
Greater Glasgow and Clyde NHS Board
Nicholas S. Reed
Kent and Canterbury Hospital
Leeds Cancer Centre at St. James's University Hospital
University Hospitals of Leicester NHS Trust
Charing Cross Hospital
Guys and St Thomas' NHS Foundation Trust
Royal Marsden - Surrey
University College London Hospitals NHS Foundation Trust
James Cook University Hospital
Velindre NHS Trust
Newcastle Upon Tyne Hospitals NHS Trust
Norfolk and Norwich University Hospitals NHS Trust
Nottingham City Hospital
Portsmouth Hospitals NHS Trust
Cancer Research Centre at Weston Park Hospital
Southend University Hospitals NHS Trust
St. Luke's Cancer Centre at Royal Surrey County Hospital
Royal Wolverhampton NHS Trust
Link to the current ClinicalTrials.gov record.
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.